Semaglutide and tirzepatide are both once-weekly injectable incretin medications, but they are not the same drug: semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. Tirzepatide has produced larger average weight-loss results in several obesity trials, but individual response varies, the approved indication matters, and there is no safe milligram-to-milligram conversion between them.
If you are comparing Ozempic, Wegovy, Mounjaro, or Zepbound, the most useful question is not simply "Which is stronger?" It is: which medication is approved for your condition, covered by your plan, tolerated by your body, and appropriate for your prescriber's goals?
What Semaglutide Is
Semaglutide is a GLP-1 receptor agonist. It mimics the action of glucagon-like peptide-1, a hormone involved in insulin secretion, glucagon suppression, gastric emptying, and appetite signaling.
In the U.S., semaglutide appears under multiple labels, including Ozempic for type 2 diabetes and Wegovy for chronic weight management. The Ozempic prescribing information and Wegovy prescribing information have different indications, dose ranges, and missed-dose rules even though both contain semaglutide.
What Tirzepatide Is
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It activates the GLP-1 pathway and also the glucose-dependent insulinotropic polypeptide pathway. That second mechanism is the reason tirzepatide is often discussed separately from older GLP-1-only medicines.
Tirzepatide is sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, with Zepbound also labeled for certain adults with obstructive sleep apnea and obesity. The Mounjaro label and Zepbound prescribing information use the same 2.5 mg to 15 mg weekly dose ladder.
Semaglutide vs. Tirzepatide at a Glance
| Comparison | Semaglutide | Tirzepatide |
|---|---|---|
| Main mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| Common U.S. brands | Ozempic, Wegovy | Mounjaro, Zepbound |
| Typical schedule | Once weekly injection | Once weekly injection |
| Dose scale | Micro-adjusted mg ladder varies by brand | 2.5 mg increments from 2.5 to 15 mg |
| Milligram conversion | Not interchangeable | Not interchangeable |
| Tracking need | Brand, dose, injection day, side effects | Brand, dose, titration step, side effects |
The key practical point: their milligrams do not compare. A 1 mg semaglutide dose is not equivalent to 1 mg, 2.5 mg, or 5 mg of tirzepatide. They are different molecules with different dosing ladders.
What the Evidence Says — and What It Does Not
Both medications have strong clinical-trial evidence in their labeled populations. Semaglutide 2.4 mg showed substantial average weight loss in the STEP program; for example, the STEP 1 trial was published in the New England Journal of Medicine and indexed on PubMed. Tirzepatide showed substantial average weight loss in the SURMOUNT program; SURMOUNT-1 is also indexed on PubMed.
Those trials are useful context, but they do not mean every person will respond the same way. Trial averages are not guarantees. People differ by starting weight, diabetes status, dose reached, side-effect tolerance, nutrition, activity, other medications, and how long they remain on therapy.
There are also head-to-head comparisons in the literature and public summaries, but the safest way to use them is carefully: they can inform expectations, not replace a prescriber's judgment. If you are switching between these medicines, the dose schedule and clinical monitoring matter more than headline percentages.
Dosing Differences Matter More Than People Realize
Semaglutide and tirzepatide are both titrated gradually to reduce gastrointestinal side effects, but their ladders are different.
Ozempic commonly starts at 0.25 mg weekly, then increases to 0.5 mg, with higher doses depending on the diabetes treatment plan. Wegovy uses a weight-management titration path toward 2.4 mg weekly when tolerated. Tirzepatide starts at 2.5 mg weekly and can increase through 5, 7.5, 10, 12.5, and 15 mg.
This is why switching is not a matter of matching numbers. If you move from semaglutide to tirzepatide, your prescriber generally treats it as a new titration ladder. Our guide to switching from Ozempic to Mounjaro explains that transition in more detail.
Side Effects and Tolerability
The most common side effects for both medication families are gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite. These often cluster around starting therapy or increasing the dose.
A person who struggled with semaglutide might tolerate tirzepatide better, worse, or about the same. The reverse is also true. Mechanism matters, but your actual response is individual. That is why prescribers often adjust the pace of titration, hold a dose longer, or step down when symptoms become hard to manage.
Seek medical advice promptly for severe abdominal pain, signs of dehydration, persistent vomiting, symptoms of gallbladder disease, allergic reactions, or any symptom your label identifies as urgent.
How to Track Either Medication
Whether you use a semaglutide tracker or a tirzepatide tracker, the basics are similar: log the medication, dose, injection day, injection site, side effects, and outcomes you and your clinician care about. The details matter most during titration and switching, when memory gets unreliable.
OffGrid Dose supports that longitudinal view: semaglutide history, tirzepatide history, injection-site rotation, and dose changes in one private record. The privacy-first GLP-1 tracker. Everything stays on your iPhone — no accounts, no cloud. You can review the full feature set, or start with the medication page that matches your prescription.
Frequently Asked Questions
Is tirzepatide better than semaglutide?
Not universally. Tirzepatide has shown larger average weight-loss results in major obesity trials, but "better" depends on your diagnosis, dose reached, side effects, coverage, contraindications, and goals. Your prescriber should interpret the evidence for your situation.
Can I convert my semaglutide dose to a tirzepatide dose?
No. There is no patient-safe milligram conversion. Semaglutide and tirzepatide are different molecules with different dose ladders, so switching should be prescribed as a clinical transition, not a math problem.
Are Ozempic and Mounjaro the same type of medication?
They are related but not identical. Ozempic contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist.
Do semaglutide and tirzepatide have the same injection day rules?
They are both once-weekly injections, but the exact missed-dose and day-change instructions differ by product label. Always check the current label for Ozempic, Wegovy, Mounjaro, or Zepbound rather than assuming one rule applies to all.
Which one is easier to tolerate?
There is no reliable answer for everyone. Both can cause nausea and other digestive symptoms, especially after dose increases. Your own side-effect log is often the best evidence for your next prescriber visit.
This article is for general educational purposes only and is not medical advice. Semaglutide and tirzepatide should be used only under the supervision of a licensed clinician. Do not start, stop, switch, or adjust doses based on a comparison article; follow your prescription label and prescriber's instructions.
Related Articles
Track this with OffGrid Dose
Log every dose, rotate injection sites, and watch your weight trend — all private and on-device.
GLP-1 tracker →